drugset / Trial / NCT00436423
A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer
Phase 2
Completed
38 enrolled
Korea University Anam Hospital
Konkuk University Hospital · collabKorea University Ansan Hospital · collabKorea University Guro Hospital · collabSeoul Municipal Boramae Hospital · collabSeoul National University Bundang Hospital · collabSeoul National University Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to Evaluate the response rate of Gemcitabine with TS-1 in Korean patient with advanced but inoperable, metastatic or recurrent pancreatic cancer who is not receiving anti cancer therapy.
Timeline
- Start
- 2006-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | TS-1 | Small molecule | 80 mg/m2 | Oral |